story of the week
Empagliflozin Decreases CV Complications and Hospitalizations in Patients With T2D and ASCVD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effects of Empagliflozin on First and Recurrent Clinical Events in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Secondary Analysis of the EMPA-REG OUTCOME Trial
Lancet Diabetes Endocrinol 2020 Dec 01;8(12)949-959, DK McGuire, B Zinman, SE Inzucchi, C Wanner, D Fitchett, SD Anker, S Pocock, S Kaspers, JT George, M von Eynatten, OE Johansen, W Jamal, M Mattheus, U Elsasser, S Hantel, SS LundFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.